Oct. 23 at 4:25 PM
$GRAL “Galleri (Grail's test) is the only available MCED test with demonstrated performance in an intended use population being screened for cancer. These new data build on the results from our first clinical implementation study, PATHFINDER, which was published in the Lancet in 2023, and showed that Galleri approximately DOUBLED THE NUMBER OF CANCERS IDENTIFIED when added to standard of care screening,” said Josh Ofman, MD, MSHS, President of GRAIL. “We’re witnessing the beginning of a transformative era for cancer screening, with these results demonstrating Galleri’s ability to detect cancers earlier, when they can be easier to treat and are potentially curable.”
